INTRODUCTION
N ewborn screening programmes provide an essential public health service. Their mission is to eliminate or reduce the mortality, morbidity and disability that results from congenital disease by ensuring that all affected infants receive early diagnosis and long-term treatment in an attempt to achieve optimal health, growth and development. Disorders commonly screened for include haemoglobinopathies, endocrine and metabolic disease, and hearing disorders.
The primary aim of haemoglobinopathy screening is the detection of sickle cell disease (SCD). SCD is a genetic disease in which the inheritance of the gene for haemoglobin S in a homozygous state (Hb SS), or with the gene for another abnormal haemoglobin (e.g. Hb SC, Hb SB0) results in the production of abnormal 'sickle-shaped' red blood cells. The disease is characterized by chronic haemolysis and vaso-occlusion, which leads to its many complications.
In early childhood, symptoms of the disease are unlikely before the age of four months, and only 6% of affected infants will be symptomatic by age six months. [1] [2] [3] The most frequent initial presenting complaint is dactylitis. The peak incidence of death occurs in the first three years, 2,3 with sepsis (especially pneumococcal) and acute splenic sequestration, an acute enlargement of the spleen associated with a fall in haemoglobin, thus worsening anaemia, to potentially life-threatening levels, being the highest causes of mortality.
Newborn screening for SCD, early enrolment into comprehensive care programmes and institution of appropriate preventive measures have proven to be extremely beneficial. Some specific measures include penicillin prophylaxis against pneumococcal sepsis. Mortality from pneumococcal sepsis decreased by 85% with penicillin prophylaxis. 4 In Jamaica, penicillin prophylaxis is given from the age of four months to four years but in other settings it is given up to the age of five years. It is generally discontinued only after pneumococcal vaccine is given at the age of four years. Teaching parents how to perform abdominal palpation to detect an enlarged spleen is another important preventive strategy. Mortality from acute splenic sequestration showed a 90% reduction with parental education and prophylactic splenectomy after two episodes of acute splenic sequestration. 5 Other general aspects of comprehensive care include routine clinic visits consisting of education, counselling, nutrition and psychosocial support as well as extensive health maintenance. This focuses on growth, development, immunization (including important vaccines against pneumococcal disease), low-threshold sick visits to allow early institution of treatment and also easy access to hospital care if the need arises.
In Jamaica, approximately 60,000 births occur annually. The trait frequency is estimated at 10%. In all, 1:150 births will have a form of SCD with 1:300 births having homozygous (Hb SS) disease. There has been no decrease in the S allele frequency in Jamaica in the past 22 years. 6 Jamaica's first experience with newborn screening occurred from 1973 to 1981 with the development of the well-described Jamaican Sickle Cell Cohort Study. 3, 7 In this study, 100,000 consecutive live births were screened at the main Government Maternity Hospital (Victoria Jubilee Hospital, Kingston). A total of 315 babies with Hb SS disease were detected, of whom eight failed to be admitted to the study. The remaining 307 patients have been followed prospectively from birth as previously described. 8 Defaulting patients were actively traced. The Jamaica Sickle Cell Cohort Study has provided invaluable information on the natural history of the disease as well as some of the major lessons in disease management, which makes it an ideal control group for this study.
Our second experience started in November 1995 when newborn screening began at the main Government Maternity Hospital in Kingston (Victoria Jubilee Hospital). It was extended to include the University Hospital of the West Indies, Kingston in October 1997 and The Spanish Town Hospital, in the neighboring parish of St Catherine, in April 1998. Together, these hospitals are responsible for 43% of births in Jamaica.
The aim of this study was to evaluate the current newborn screening programme and where appropriate to make comparisons between clinical outcomes of Hb SS patients and clinical outcomes of Hb SS patients identified as a result of the Jamaica Sickle Cell Cohort Study.
METHODS
This was a retrospective analysis of data available from the databases of the newborn screening programme and the clinic at the Sickle Cell Unit (SCU), Tropical Medicine Research Institute, Jamaica. Cord blood was collected at birth on a Guthrie card, which was then transported to the SCU laboratory for analysis. Patient characteristics, such as mother's name, address, delivery hospital, infants' date of birth (DOB), screening results, were recorded in the newborn screening database. Infants with cord blood screening results suggestive of a haemoglobinopathy or with an inappropriate specimen or unclear results were notified for confirmatory tests by letter. Infants who fail to show were traced by a research nurse and parents were encouraged to bring their infant to the SCU for further testing. The laboratory methods used for screening and confirmatory testing are described before. 9 Infants confirmed to have a diagnosis with a form of SCD were enrolled into the clinic at the SCU. Because of laboratory techniques used, a small number of infants with an initial diagnosis of Hb SS genotype may change to a form of sickle-thalassemia (Hb SB) as they age. The overall aim was to enroll infants into the clinic before the age of four months (Figure 1 ). At their first clinic visit, parents were counselled and taught how to perform splenic palpation. Their next visit was scheduled for age four months, at which time penicillin prophylaxis would be started. Routine clinic visits then occurred every three months until age five years after which routine visits occurred every six months. Patients are seen at any time for sick visits. Information (clinical and laboratory) from each visit is recorded in the clinic database.
As of July 2006, 150,803 infants had cord blood screening. At least 889 infants had phenotype results suggestive of possible SCD (Table 1 ). Of these, 435 infants had confirmatory genotypes of Hb SS disease. Data relating the outcome of all confirmatory tests is not readily available from the current newborn screening database as there is no link between the newborn screening programme and clinic databases.
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Statistical analysis
Kaplan-Meier survival curves were presented and compared using the log-rank test. There were three time variables. The first variable we defined as the time to death from birth where subjects were censored if they were lost to follow-up or were alive at the end of the study. The second variable we defined as time from birth to first hospital admission. Subjects were censored if they were lost to follow-up before their first hospital admission. The third time variable involves a multiple failure time approach where each subject experiences multiple events of serious illness since birth. Analysis was performed with Stata software package.
RESULTS
The study sample consisted of 435 patients with Hb SS disease. No data was available for 40 patients who did not return for a first visit after confirmatory tests. They were excluded from further analysis. The remaining 395 patients provided 2040 years of patient follow-up. The median length of follow-up was 5.1 years (range 0.15-10.9 years). Approximately 68% of patients presented for their first visit less than four months of age and just fewer than 10% presenting over the age of one year ( Table 2) .
Seven deaths (1.8%) occurred during the study period with a patient age range of two months to 10 years compared with 17.6% for the same age in the Jamaican Sickle Cell Cohort Study. 3 The survival curve for the study population for the most part remains in the probability range of 0.89-1.00, which indicates that at least 89% of subjects live longer than 10 years (Figure 2) .
A previous analysis of the pattern of survival within the Jamaica Sickle Cell Cohort Study stratified according to date of birth (enrolment period) had demonstrated improved survival in cohort subjects born in later third of the study enrolment period, i.e. between January 1979 and December 1981. 10 This pattern of continued improved survival in subjects more recently enrolled was further accentuated when the survival of this study was included ( Table 3) . Thus there was a statistically significant difference between the groups (Po0.0001) with the current group having a better survival rate compared with all other groups (Figure 3 ).
There was a statistically significant difference between the groups (P ¼ 0.0146) when time to first hospital admission was assessed. For the first year, the rates of admissions seem to be fairly similar; however as the subjects age, there seems to be a separation of the survival curves, with the study group being the most likely to be admitted to hospital (Figure 4 ). This earlier time to first admission in the current group most likely reflects a lower threshold for admitting sick patients, earlier intervention and consequently better outcomes. However, the overall proportion of patients admitted in the study group (72%) was lower than the number admitted in the control groups (85%). Hospital admissions are summarized in Table 4 . There was a statistically significant difference between the groups (P ¼ 0.041) in the proportion of serious illness ( Figure 5 ), defined as an episode of acute chest syndrome, stroke, proven (culture-positive) sepsis or acute splenic sequestration. Overall, the current group is experiencing less serious illness than the other groups.
Acute chest syndrome, onset of acute respiratory signs/ symptoms with radiological evidence of a new pulmonary infiltrate, was the most common clinical (non-death) event. This accounted for almost 50% of all clinical events (Table 5 ). This occurred in 142 patients. 43 patients had one episode, 42 patients had two episodes and 57 patients had three or more episodes.
Acute splenic sequestration was also responsible for a significant number of clinical events (32%), but as will be shown later, is no longer a significant cause of mortality. Aplastic crisis and salmonella sepsis were the most common infection-related events (4% each). Invasive pneumococcal disease accounted for 2% of all events ( Table 5 ).
The incidence of invasive pneumococcal disease decreased between the two cohort groups, especially in the three years and under age group, the age group at greatest risk for pneumococcal disease (Table 6 ). This improvement reflects the benefits of penicillin prophylaxis.
A greater number of episodes of acute splenic sequestration were detected, a reflection of the parental education programme (Table 7) . However, only one death occurred in this study representing 0.53% of total episodes, demonstrating the benefits of early detection and intervention.
DISCUSSION
This study continues to demonstrate the benefits of, and as such shows support for, newborn screening and early interventions in SCD. This is evidenced by decreasing mortality rates, improved survival estimates and fewer proportion of hospital admissions and episodes of serious illness when comparing the Jamaican Sickle Cell Cohort Study to the current study patients.
One may argue that improved morbidity and mortality is not necessarily attributable to screening but merely preventive strategies. However, it is important to note that the (Figure 3) , when early-age interventions had not yet been implemented, 14% of children died in the first two years of life compared with less than 1% for whom preventive strategies were implemented at an early age in the current study group. Therefore, it is extremely important that institution of preventive strategies occur at an early age for them to be beneficial. Newborn screening allows for early detection. In the absence of newborn screening, delays in symptomatology as well as delays in diagnosis are some of the factors which interfere with important early-life interventions. A study of the Jamaican Sickle Cell Cohort Study showed that symptoms are unlikely to start before age six months, with about 32% of Hb SS patients becoming symptomatic by age one year, 61% by age two years, 78% by age three years and 90% by age five years. 1 A study of patients symptomatically referred to the SCU showed that only 25% of patients not diagnosed at birth were diagnosed by symptoms by age two years, 11 despite data which shows that 61% of patients will be symptomatic by age two years. Additionally, a clinic-based study in Jamaica showed that 65% of children with Hb SS disease, not identified at birth, will not benefit from important early-life interventions. 12 Without a regime of early detection via newborn screening and comprehensive follow-up, morbidity and mortality are likely to remain high in the early childhood period. At the same time, this study also highlights some of the areas for continued focus and research development. Acute chest syndrome remains a significant cause of morbidity and also mortality. In all, 70% of our patients had two or more episodes of acute chest syndrome. Recurrent acute chest syndrome increases the risk for the development of restrictive chronic sickle lung disease. 13 Hydroxyurea has been shown to be beneficial in the management of patients with recurrent acute chest syndrome, but a better understanding of the pathogenesis of this condition will more likely lead to fewer episodes, better management and outcomes. 14 The epidemiology and cause of the aplastic crisis in SCD is well known. 3 It still remains a significant cause of clinical events supporting the need for continued research towards the development of a vaccine for human parvovirus.
The study also highlights the design of the newborn screening programme and its importance for such programmes to be effective. A recommended five-tier system that includes screening, follow-up, diagnosis, management and evaluation has been described. 15 This must be a comprehensive system with meticulous data collection and documentation, both of which are important for research, problem solving and programme evaluation. Ideally, this system should be governed by an administrative unit responsible for general oversight of the programme.
The current system, although not yet ideal, is providing an essential and beneficial newborn screening service and should be maintained. Its design mimics the recommended design; however, there are many deficiencies that need to be addressed. Of utmost importance is the development of an administrative unit with appropriate governance and funding to support the system. This will allow for regular programme evaluation and hopefully island wide expansion of the programme.
Better data collection and collaboration between tiers can only lead to a more efficient system. Currently, complete information on outcome of screening and confirmatory tests is unavailable. This is because there is a poor link between the newborn screening database in which results of cord blood screening and some confirmatory tests are stored and the SCU database when patients are enrolled. Likewise, information on outcomes of patients with forms of SCD other than homozygous sickle cell disease is not easily obtained. In addition, the significant number of patients, for whom no follow-up data is available, having failed to show after confirmatory tests were done, reflects a need for better tracing of missing patients. These are indications of a failure of the system to capture and highlight relevant information needed for evaluation and patient management.
Four months is the age by which early intervention measures such as penicillin prophylaxis should be started. In some countries, these measures are started at age two months, again highlighting the early age for implementing preventive strategies. Therefore, this allows a reasonable amount of time during which every effort should be made to trace patients. Approximately 68% of our patients presented for their first clinic visit by age four months. This is acceptable but should be improved.
There can be no question that newborn screening programmes to detect SCD are essential services, especially in countries such as Jamaica where the burden of disease is high. However, these programmes are not mere tests, and must be appropriately designed to provide an effective, comprehensive system comprising of screening, follow-up, diagnosis, management and evaluation, which will allow for optimal growth, health and development of those affected with the disease. Comparison before and after in the Jamaica Sickle Cell Cohort Study and also in the current study sample
